Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), says its researchers have developed computational methods that enable its AlzoSure® Predict prognostic technology to accurately identify individuals who will rapidly progress to AD within two years’ time.
More than 95% of the patients above the new computational “cutoff” used to define “rapid progressors” were shown to progress to AD within two years’ time, regardless of their baseline diagnosis. Using a modified form of the new approach, Diadem was able to do even better, accurately identifying a cohort where 100% of the patients progressed to AD within two years, while none of the patients not included in the modified cutoff cohort did so.
The computational analysis were developed using a relatively limited number of patient samples from major international longitudinal patient databases. The results will be further validated and expanded, and these analyses are already underway using global cohorts of qualified biological samples.
“We believe that this new refinement of our AlzoSure® Predict test could not be more timely, as the FDA approval of lecanemab, which shows promising signs of slowing cognitive decline in early AD, highlights the need for accurate and economical screening tools to select patients most likely to benefit from early treatment,” Diadem CEO Paul Kinnon noted. “The cost benefit trade-off in choosing whether or not to take these drugs, with their potential side effects and high costs, is shifted when a patient is identified by AlzoSure® Predict’s new computational cutoff as having a high probability of advancing to AD in just two years’ time.
“The additional feature should also be valuable for drug development, since it will allow researchers to select “rapid progressor” patients for clinical testing who are almost certain to develop AD within two years, enabling a much faster and more cost-effective read-out of clinical trial results.”
Diadem is currently expanding its initial confirmatory studies of the new computational cutoff. It plans to present data on its results at scientific meetings later this year. The company is also planning for the commercial launch of AlzoSure® Predict in the U.S. this year, in collaboration with a major diagnostics partner.
AlzoSure® Predict can allow drug developers to screen, enrich and stratify patient populations to facilitate Alzheimer’s disease clinical trials. Use of the test enables researchers to identify with high confidence individuals who will experience a decline to Alzheimer’s dementia years in advance of diagnosis .
Clinical studies show that AlzoSure® Predict is able to predict cognitive decline to AD dementia with an AUC greater than 90%, regardless of the cognitive, amyloid or tau status of the patient at the time of testing.
AlzoSure also demonstrated superiority compared to Pib-PET amyloid imaging in predicting decline to AD dementia in patients before, or with, early signs of cognitive deficits.
The company is in the final stages of further validating its earlier findings using longitudinal data from the U.S.-based Alzheimer’s Disease Research Centers (ADRC) and Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohorts.
AlzoSure® Predict is a non-invasive biomarker blood test that can identify with high accuracy whether individuals over the age of 50 with signs of cognitive impairment will or will not progress to Alzheimer’s disease up to six years before diagnosis.
The test uses a proprietary antibody (U-p53AZ) to measure blood levels of a conformational variant of the p53 protein that has been implicated in the pathogenesis of AD. Previous studies suggest that this p53 variant has utility as a diagnostic and as a predictive biomarker to identify individuals likely to progress to AD up to six years before symptoms appear.
The utility of AlzoSure® Predict is supported by clinical data from a large longitudinal study that was the basis for AlzoSure® Predict’s Breakthrough Device designation from the U.S. Food & Drug Administration and its CE-IVD marking in the EU.
AlzoSure® Predict requires only 1mL of blood and 4 to 5 days for analysis to detect AD at the asymptomatic and prodromal (early symptomatic) stage, with an accuracy greater than 95% up to at least 6 years in advance of the clinical onset of symptoms.
Previous research also demonstrated that AlzoSure® Predict can discriminate between the different kinds of dementia with high accuracy.
SOURCE: Diadem SpA
This test together with lecanemab may actually begin to make a dent in the tragedy of dementia.